Could probiotics help antibiotics work better for gut bacteria overgrowth?

NCT ID NCT07426705

First seen Mar 08, 2026 · Last updated Jun 21, 2026 · Updated 13 times

Summary

This study looks at whether adding a specific probiotic (containing Enterococcus faecium and Bacillus subtilis) to the antibiotic rifaximin can improve treatment for small intestinal bacterial overgrowth (SIBO), a condition that causes bloating, pain, and diarrhea. About 100 adults with SIBO and irritable bowel syndrome will get either the probiotic or a placebo after antibiotic therapy. The goal is to see if the probiotic helps clear the overgrowth and prevents it from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROME (SIBO) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

multispecies probiotic containing Enterococcus faecium and Bacillus subtilis

What this could lead to

If it works, this could point toward a way to improve antibiotic treatment for SIBO and lower the chance of symptoms coming back.

What could go wrong

This is a small, early-phase trial with only 100 participants, so results may not apply to everyone. Probiotics can sometimes cause bloating or gas, and the added benefit over antibiotic alone is uncertain.

Conditions

The condition(s) this trial relates to.

irritable bowel syndrome small intestinal bacterial overgrowth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.